WHILE Silicon Valley chases artificial general intelligence with billion-dollar training runs, a burgeoning crop of Chinese AI firms has been achieving what the entire industry is striving for: sustainable profitability in specialized markets.
Thanks to China’s industrial scale and market volume, these notoriously R&D-heavy tech ventures are now cashing in on their early commercial viability.
A financial report this week brought an encouraging glimpse into the momentum. XtalPi, an AI drug discovery company listed in Hong Kong, turned a profit of 134.6 million yuan (approximately US$19.5 million) in 2025, following a loss of 1.5 billion yuan the year before. This turnaround occurred even as the tech firm increased its R&D expenditure by approximately 36 per cent. Such a success serves as a microcosm of China’s broader strategy in the global tech race: rapidly integrating AI with its robust industrial base to capture premium advantages in specialized sectors.
XtalPi, leveraging AI to facilitate drug discovery for global biopharmaceutical firms, made multiple commercial progress last year, including advancing targeted cancer therapies and pediatric disease treatments into clinical trials.
Xinhua
#TheGlobalNewLightOfMyanmar